Ozempic (semaglutide) is effective for managing type 2 diabetes and promoting weight loss, but it comes with a significant list of downsides that range from common digestive discomfort to serious safety concerns. Between 15% and 23% of users experience nausea alone, and the problems extend well beyond an upset stomach. Here’s what you should know before starting or continuing treatment.
Digestive Side Effects Are Extremely Common
The most frequent complaint from Ozempic users is gastrointestinal distress. In clinical trials, nausea affected 15% to 23% of patients, making it the single most reported side effect. Diarrhea followed at 8% to 14%, and constipation affected 3% to 7%. These symptoms tend to be worst during the first few weeks and when the dose is increased, and they do improve for many people over time. But for some users, the nausea and digestive problems persist for months or never fully resolve.
Beyond the common symptoms, there’s a rarer but more serious risk. A University of British Columbia study analyzing 16 million U.S. patient records found that GLP-1 drugs like Ozempic carried a 3.67 times higher risk of gastroparesis compared to another weight loss medication. Gastroparesis is a condition where the stomach can’t empty food normally, leading to severe nausea, vomiting, bloating, and abdominal pain. While the absolute risk is low for any individual, with millions of people now using these drugs worldwide, even a rare complication can affect hundreds of thousands of people.
You Lose Muscle, Not Just Fat
One of the most underappreciated downsides of Ozempic is that a large portion of the weight you lose isn’t fat. A systematic review published in Circulation found that 20% to 50% of total weight lost on GLP-1 drugs was lean mass, which is primarily muscle. In one major clinical trial (STEP 1), participants on semaglutide lost an average of 15.2 kg, and roughly 45% of that weight loss came from lean mass rather than fat.
That matters for several reasons. Muscle is metabolically active tissue that helps regulate blood sugar, protects your joints, and keeps you physically functional as you age. Losing a significant amount of muscle can lower your resting metabolism, making it harder to maintain weight loss long term. For older adults especially, losing muscle mass increases the risk of falls, fractures, and reduced mobility. Resistance training and adequate protein intake can help offset some of this loss, but the drug’s effect on body composition is a genuine tradeoff that doesn’t get enough attention.
Weight Comes Back When You Stop
Ozempic is not a one-and-done treatment. A 2025 systematic review in The BMJ found that people who stopped taking newer, more effective versions of these drugs regained an average of 9.9 kg within the first year. The researchers projected a full return to baseline weight by about 1.5 years after stopping treatment.
This means most people need to stay on the medication indefinitely to maintain their results, which raises both cost and long-term safety questions. If you stop because of side effects, insurance changes, or supply shortages, the weight is likely to return. And because you may have lost significant muscle during treatment, you could end up at the same weight but with a worse body composition than before you started.
“Ozempic Face” and Accelerated Aging
Rapid weight loss from Ozempic can cause noticeable changes in facial appearance, sometimes called “Ozempic face.” The fat layer just under your facial skin provides structure and fullness. When you lose weight quickly, that subcutaneous fat disappears from the face and neck, creating a hollowed, gaunt, or sagging look. At the same time, rapid weight loss lowers levels of collagen and elastin, two proteins that keep skin firm and elastic. The result can mimic years of aging in a matter of months, according to Cleveland Clinic dermatologists. The effect is more pronounced in people over 40, who naturally have less facial fat to begin with.
The Thyroid Cancer Warning
Ozempic carries the FDA’s most serious label warning, a boxed warning, for the risk of thyroid C-cell tumors. In animal studies, semaglutide caused dose-dependent thyroid tumors at exposure levels comparable to what humans receive. Whether this translates to actual cancer risk in humans remains unknown. Because of this uncertainty, Ozempic is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. Symptoms to watch for include a lump in your neck, difficulty swallowing, or persistent hoarseness.
Eye Complications for People With Diabetes
For people with diabetes who already have some degree of diabetic eye disease, starting Ozempic can temporarily worsen the condition. This happens because rapid improvements in blood sugar control can paradoxically stress the small blood vessels in the retina. It’s a known phenomenon that has been observed with other diabetes treatments that lower blood sugar quickly, not just semaglutide. If you have existing diabetic retinopathy, your eye health should be monitored closely after starting treatment.
The Cost Problem
Ozempic has a list price of about $998 per month. Even with discount programs or pharmacy coupons, the out-of-pocket cost without insurance typically runs $199 to $499 or more per month. Insurance coverage is inconsistent at best. Most plans don’t cover medications prescribed specifically for weight loss. Medicare Part D covers Ozempic for diabetes but is federally prohibited from covering weight loss drugs. Medicaid coverage varies by state, with only 13 states covering weight management medications.
Given that most people need to stay on the drug long term to maintain results, you’re looking at a potential expense of several thousand dollars per year, indefinitely. A gap in coverage or affordability doesn’t just mean wasted money on past prescriptions. It likely means regaining the weight you lost.
Pancreatitis: A Concern That May Be Overstated
Early studies raised alarms about a possible link between GLP-1 drugs and acute pancreatitis. However, more recent and rigorous research has largely put this concern to rest. A propensity-matched analysis of U.S. patients with type 2 diabetes found that the risk of pancreatitis was similar between those taking GLP-1 drugs and those who weren’t. Over a five-year period, patients on GLP-1 drugs actually had a statistically lower rate of pancreatitis. The absolute risk in both groups was very low. That said, pancreatitis is a known precaution on the label, and severe abdominal pain that doesn’t go away should always be evaluated promptly.